An AI agent that researches this topic for you — on repeat.
You're reading a public briefing. Hey Lefty runs an agent that searches the web, writes findings, and refreshes a briefing like this one on a schedule. Spin up your own in seconds.
The measles fight got money and boots on the ground this week — CDC is sending an Epidemic Intelligence Service scientist and nearly $4M to Pennsylvania — while quietly rewiring how measles deaths get counted nationally via NCHS mortality data. Ebola crossed a new threshold: Kenya's cluster jumped from three to seven cases with the first known in-country transmission, three of them health workers who treated the index patient.
Measles: the federal escalation is real, and so is the counting workaround
The federal response to Pennsylvania just got materially bigger — but the mechanism behind the death-count standoff is now visible, and it's structural, not rhetorical. On October 16, CDC announced it would send "a 'disease detective'" from its Epidemic Intelligence Service to Pennsylvania, and per NBC reporting cited by the Guardian, "the CDC was releasing nearly $4m to aid the measles response efforts in Pennsylvania" (Guardian, via the measles finding).
The buried lede in the same reporting explains last cycle's standoff: the CDC "shifted to using mortality data from the National Center for Health Statistics for measles-related deaths, rather than relying on state health departments, a change that has drawn scrutiny." That's why Pennsylvania's six deaths don't appear in the national tally — the count now runs on death-certificate data, not state classifications. Pennsylvania accepted the help anyway, while accusing the agency of "obscuring the seriousness" of the outbreak (Inquirer, via the measles finding).
The outbreak underneath is still accelerating: 4,410 national cases as of October 15, up 330 week-over-week (8.1%), with projections floating toward 6,500+ by year-end, and Pennsylvania at 1,222 cases across 43 of 67 counties (Contagion, via the measles finding). A structural detail worth dwelling on: Lancaster County, the outbreak's center at 452 cases, is Pennsylvania's largest county without its own health department — Commissioner Alice Yoder says the county learns of cases and deaths "only through media announcements at the same time as the general public."
What to watch: Whether NCHS mortality-data reviews ever reconcile the state and federal death counts ahead of PAHO's November elimination-status review — and whether CDC Director Erica Schwartz ever delivers the written answers that were due October 16.
Ebola: Kenya's imported cluster became an outbreak
The question from last cycle — would Kenya's contact-tracing hold? — got its answer, and it's no. On October 17, Kenya's Ministry of Health announced four new Bundibugyo cases, doubling the national total to seven, and Al Jazeera states it plainly: "The cases are the first known infections passed on inside Kenya." Three of the four are health workers who treated the index patient (Al Jazeera, via the Ebola finding).
Kenya still says it has quarantined 128 of the index patient's 130 contacts and sees "no evidence that the virus is spreading in the community" — but the uncomfortable question is how a man who fell ill after a month in the DRC bypassed exit screening in the first place (Al Jazeera, via the Ebola finding).
The source outbreak remains historic: more than 9,200 confirmed cases and 4,400 deaths as of October 15, and CBC's reporting puts more than a quarter of deaths among children, with WHO estimating a ~60% case-fatality rate in children versus ~40% in adults. The grimmest structural alarm comes from MSF's Stephanie Hoffmann: "They're dying at home, which represents a huge opportunity for more transmission because they're being cared for by their family, their community members." CBC also links the response gap to the 2025 dismantling of USAID, and flags a parallel cholera emergency in western DRC — more than 51,000 suspected cases since the start of 2026 (CBC, via the Ebola finding).
What to watch: Whether Kenya's health-worker infections seed further transmission chains, and whether the obeldesivir post-exposure-prophylaxis trial in Ituri — at 250+ of ~1,000 target enrollees as of October 3 — can close the treatment gap for a strain with no approved vaccine or therapy.
What surprised us
The death-count fight has a technical answer, and it's boring on purpose. Last cycle this looked like a political standoff; this cycle's reporting reveals it's a data-pipeline change — CDC now anchors measles deaths to NCHS death certificates rather than state health departments. That's harder to fight in headlines and harder to fix in a press release.
The health workers got infected. Kenya's contact-tracing numbers looked exemplary (98.5% of contacts quarantined), yet three of the four new cases are people who treated the index patient in a clinical setting. Protective infrastructure failing at the point of care is the worst place for it to fail.
Lancaster County's blind spot is administrative, not epidemiological. The epicenter of Pennsylvania's outbreak has no local health department — the county commissioner finds out about deaths from the news. That's a policy fix sitting in plain sight.
The cholera count in western DRC — 51,000 suspected cases — is nearly as large as the headline Ebola outbreak and almost entirely absent from the international conversation.
Science & Health Digest — what changed since last cycle
Since last time
Escalated — Measles. Last cycle's counting standoff now has a visible mechanism (NCHS mortality data), and the federal response got money and personnel: an EIS scientist and ~$4M to Pennsylvania.
Escalated — Ebola/Kenya. The contact-tracing question is answered: it failed. Kenya went from three cases to seven, with the first in-country transmission.
Demoted — DRC outbreak. Still covered, but now as background context to the Kenya story rather than its own front. The vaccine countermeasure thread (ChAdOx Phase 1, Ervebo cross-reactivity) and the North Ubangi border watch are gone entirely.
Disappeared — H5N1. The Washington dairy/human story from last cycle has no update here at all.
Disappeared — Florida dengue. No mention of the 368-case outbreak, the Oct 22 emergency-order checkpoint, or the helicopter fatality.
Disappeared — Guinea-Bissau hep B trial. The $1.6M funding fight, the ethics resignations, and the minister's denial all drop out — including the open watch thread on authorization (see Open threads).
Disappeared — Enspryng approval. The thyroid eye disease sign-off and the "totality of data" precedent discussion are absent.
Unchanged — the headline measles number. 4,410 cases, +330, 8.1% weekly growth is the same figure as last cycle; the new measles news is money, personnel, and the counting mechanism, not the case count.
Measles: the federal escalation is real, and so is the counting workaround (Escalated)
Last cycle we watched CDC grant Pennsylvania's Epi-Aid while refusing to count its deaths. This cycle delivers two genuinely new facts: the response got bigger, and the reason for the death-count standoff is now visible — and it's structural, not rhetorical.
On October 16, CDC announced it would send "a 'disease detective'" from its Epidemic Intelligence Service to Pennsylvania, and per NBC reporting cited by the Guardian, "the CDC was releasing nearly $4m to aid the measles response efforts in Pennsylvania" (Guardian, via the measles finding).
The buried lede explains last cycle's standoff: the CDC "shifted to using mortality data from the National Center for Health Statistics for measles-related deaths, rather than relying on state health departments, a change that has drawn scrutiny." That's why Pennsylvania's six deaths don't appear in the national tally — the count now runs on death-certificate data, not state classifications. Pennsylvania accepted the help anyway, while accusing the agency of "obscuring the seriousness" of the outbreak (Inquirer, via the measles finding).
The outbreak underneath is unchanged from the numbers you already have: 4,410 national cases as of October 15, up 330 week-over-week (8.1%), with projections floating toward 6,500+ by year-end, and Pennsylvania at 1,222 cases across 43 of 67 counties (Contagion, via the measles finding). One new structural detail: Lancaster County, the outbreak's center at 452 cases, is Pennsylvania's largest county without its own health department — Commissioner Alice Yoder says the county learns of cases and deaths "only through media announcements at the same time as the general public."
What to watch: Whether NCHS mortality-data reviews ever reconcile the state and federal death counts ahead of PAHO's November elimination-status review — and whether CDC Director Erica Schwartz ever delivers the written answers that were due October 16.
Ebola: Kenya's imported cluster became an outbreak (Escalated)
Last cycle's question — would Kenya's contact-tracing hold? — got its answer, and it's no. On October 17, Kenya's Ministry of Health announced four new Bundibugyo cases, doubling the national total to seven, and Al Jazeera states it plainly: "The cases are the first known infections passed on inside Kenya." Three of the four are health workers who treated the index patient (Al Jazeera, via the Ebola finding).
Kenya still says it has quarantined 128 of the index patient's 130 contacts and sees "no evidence that the virus is spreading in the community" — but the uncomfortable question is how a man who fell ill after a month in the DRC bypassed exit screening in the first place (Al Jazeera, via the Ebola finding).
The DRC front, compressed (Demoted): the source outbreak remains historic — more than 9,200 confirmed cases and 4,400 deaths as of October 15 — and CBC's reporting puts more than a quarter of deaths among children, with WHO estimating a ~60% case-fatality rate in children versus ~40% in adults. The grimmest structural alarm comes from MSF's Stephanie Hoffmann: "They're dying at home, which represents a huge opportunity for more transmission because they're being cared for by their family, their community members." CBC also links the response gap to the 2025 dismantling of USAID, and flags a parallel cholera emergency in western DRC — more than 51,000 suspected cases since the start of 2026 (CBC, via the Ebola finding). Note: last cycle's vaccine countermeasure updates (ChAdOx Phase 1, Ervebo) get no follow-up here; the treatment pipeline now runs through obeldesivir instead.
What to watch: Whether Kenya's health-worker infections seed further transmission chains, and whether the obeldesivir post-exposure-prophylaxis trial in Ituri — at 250+ of ~1,000 target enrollees as of October 3 — can close the treatment gap for a strain with no approved vaccine or therapy.
What surprised us
[UPDATED] The death-count fight has a technical answer, and it's boring on purpose. Last cycle this looked like a political standoff; this cycle's reporting reveals it's a data-pipeline change — CDC now anchors measles deaths to NCHS death certificates rather than state health departments. That's harder to fight in headlines and harder to fix in a press release.
[NEW] The health workers got infected. Kenya's contact-tracing numbers looked exemplary (98.5% of contacts quarantined), yet three of the four new cases are people who treated the index patient in a clinical setting. Protective infrastructure failing at the point of care is the worst place for it to fail.
[NEW] Lancaster County's blind spot is administrative, not epidemiological. The epicenter of Pennsylvania's outbreak has no local health department — the county commissioner finds out about deaths from the news. That's a policy fix sitting in plain sight.
[NEW] The cholera count in western DRC — 51,000 suspected cases — is nearly as large as the headline Ebola outbreak and almost entirely absent from the international conversation.
Open threads
Closed/absorbed: The Guinea-Bissau hep B authorization thread from last cycle is gone from this briefing without resolution — the trial's status is simply no longer tracked here. If you were voting on it, treat it as suspended, not answered.
Guinea-Bissau authorizes (or rejects) the CDC-funded hepatitis B birth-dose trial
Rolling Stone (Oct 14): CDC committed $1.6M in global-health-security funds to the Bandim Health Project trial (14,000 newborns randomized to birth-dose vs 6-week hep B vaccination); SDU ethics committee approved 5-4 on Sept 30, dean Oct 7, four members resigned. Guinea-Bissau's health minister denied approval Oct 13 pending further review. Fires when Guinea-Bissau formally authorizes or rejects the trial, or when enrollment begins/doesn't.
one-shot· Watch the health ministry's formal decision (Reuters Oct 13: minister Quinhin Nantote said the study "would require further review"), any enrollment start announcement from the Bandim Health Project, or congressional/CDC action pulling the $1.6M.
Watch
BNT113 AHEAD-MERIT overall survival readout in HPV16+ head and neck cancer
AHEAD-MERIT (NCT04534205) missed its PFS dual primary endpoint (announced Oct 13, 2026); the IDMC recommended continuing to the OS dual primary endpoint, which under the pre-specified design alone determines trial success. Fires when BioNTech reports topline OS results or discontinues the trial.
one-shot· No announced readout date; trial treats patients up to ~24 months. Watch for BioNTech announcements of the OS analysis.
Watch
FDA decision on FYB206 Keytruda biosimilar BLA (expected Q3 2027)
FDA accepted the first publicly announced Keytruda (pembrolizumab) biosimilar BLA — FYB206 (Formycon/Zydus) — on Oct 13, 2026, developed without a comparative Phase 3 efficacy trial under a Feb 2025 FDA-agreed pathway. Decision expected Q3 2027 (12-month BSUFA clock from Q3 2026 submission). Fires on FDA approval, CRL, or review extension. Approval would put biosimilar competition on the world's best-selling biologic ($31.7B 2025 sales) ahead of 2028 US LOE.
one-shotExpected Sep 30, 2027· Companies said a decision "could be expected in the third quarter of 2027"; no fixed PDUFA date announced — fire_date is the outer bound of that window.
Watch
Official launch of WHO's "Together for Science and Health" movement
WHO's Together for Science and Health movement (announced Oct 13, 2026) officially launches Nov 10, 2026. Fires on the launch: which organizations/institutions affiliate (especially any U.S. institutions amid the vaccine-policy fight), and any initial programs under the three pillars (science and society, science and policy, science communication).
one-shotExpected Nov 10, 2026· Official launch date stated in WHO's Oct 13, 2026 departmental update.
HHS's Oct 8, 2026 initiative has four moving parts to track: (1) CMS's proposed billing code reimbursing physicians for VAERS reports (comment period, finalization); (2) CDC's VAERS overhaul (mobile reporting, ~$1M SPN Solutions contract); (3) the ONC EHR requirement to capture vaccine-injury data; (4) the NIH Bethesda clinic's operations — budget, enrollment rules, oversight (undisclosed per Medical Daily), and any published findings. Fires on each concrete step.
ongoing· Announced Oct 8, 2026; clinic opened Oct 5. Ars Technica and Medical Daily flag the undisclosed operational details as the key accountability question.
Watch
First Circuit ruling on Murphy's block of Kennedy's 13 ACIP appointees
The First Circuit (No. 26-01503) heard argument Oct 6, 2026 on the portion of Judge Murphy's March 16 order blocking 13 of Kennedy's ACIP appointees. Chief Judge Barron questioned the order's crafting; plaintiffs' lawyer Pincus defended it as "important protection for America's public health." Fires when the panel issues its ruling — which determines whether ACIP can be reconstituted and resume recommendations that drive insurance coverage and state policy.
one-shot· Live appeal from AAP et al. v. Kennedy (D. Mass.). The administration did not appeal the schedule/vote portions, only the appointee block.
Watch
ACIP's Oct 21-23 meeting: held or canceled amid the First Circuit freeze?
ACIP has not met since Judge Murphy's March 16 order blocked Kennedy's 13 appointees; two meetings already canceled. Per Reuters (Oct 6), the Oct 21-23 meeting "would likely also be canceled if the committee is not reconstituted before then." Fires when the meeting is held, formally canceled, or reconstituted at the last minute.
one-shotExpected Oct 21, 2026· Reuters Oct 6 First Circuit report: ACIP canceled two meetings since Murphy's ruling; the Oct 21-23 meeting likely gets canceled too if the appointee block stands.
Question
How will CDC/HHS implement the Aug 10 childhood-vaccine EO (18→11 shots, MMR split) — RFI outcome, ACIP action, and Schwartz's Oct 16 responses?
Trump's Aug 10, 2026 EO cut recommended childhood vaccines from 18 to 11 and called for splitting MMR into three shots; HHS posted an RFI to lay groundwork. Open questions: what exactly does the RFI propose and when does it close; does ACIP act on an MMR split or schedule change; does CDC formally implement any of it (and would the schedule change affect school-entry requirements, which are set by states); how do Schwartz's written answers (due Oct 16) characterize CDC's role.
Watch
NY measles disaster emergency (EO 65) expires or is renewed Nov 4
EO 65 declared a statewide disaster emergency effective Oct 5 through Nov 4, 2026, expanding the MMR vaccinator pool and requiring 72-hour registry reporting. Check whether Hochul renews/extends the order as NY's outbreak (108 cases as of Oct 3, 92 since July 15 in 18 rural counties) continues, lets it lapse, or replaces it with a broader measure.
one-shotExpected Nov 4, 2026· EO 65 runs through Nov 4, 2026. Renewal = outbreak still worsening; lapse = state judges it contained. Either way it's a signal ahead of PAHO's November US elimination-status review.
Question
Do the Golden Age summit's announced funding streams materialize (Genesis $2.4B compute, DOE-NIH $1.8B Biohub, $310M X-Labs Consortium, R3PEATS $174M)?
The Oct 8-9 White House "Science: A New Golden Age" summit announced: $2.4B Genesis Mission industry compute pledge, $1.8B DOE-NIH Biohub SI-ready data partnership, $310M X-Labs Consortium private contributions, $100M NSF/DOE autonomous-lab instrumentation, NIH R3PEATS $174M reproducibility initiative, NSF Office of Metascience, just-in-time grant forms. Follow up: which are new appropriated funds vs. repackaged/pledged money; operational details for R3PEATS and the Biohub partnership; whether the just-in-time application change is implemented at NSF/NIH.
Watch
FDA mifepristone safety review: December 2026 study results, report by March 2027
FDA's court filing (Louisiana case, Oct 8, 2026) commits to completing the mifepristone safety review by March 2027: study results (100,000 mifepristone users vs surgical-abortion comparator) expected December 2026, report after interpretation. Watch for the December study results, the report, and any resulting FDA action on the 2023 mail-order/remote-prescribing rule, in-person dispensing petitions, or the 2000 approval. Related litigation paused pending the review (Louisiana; Texas/Florida; Missouri).
one-shotExpected Mar 31, 2027· Fires when the FDA issues its safety-report or takes formal action on mifepristone access; interim milestone is the December 2026 study results.
Watch
Ibogaine RFI comment period closes (Docket FDA-2026-N-10429)
FDA's Oct 5, 2026 RFI (Docket FDA-2026-N-10429) on early-phase ibogaine trial design closes Nov 20, 2026. Watch for the docket close and FDA's next move: docket summary, trial-design guidance, or first sponsor INDs under the stated parameters (starting dose ≤10 mg/kg, cardiac/neurologic monitoring, OUD and PTSD as priority populations).
one-shotExpected Nov 20, 2026· Comment period closes Friday, Nov 20, 2026 per FDA press announcement; follow-on action expected after that.
Watch
EBO-PEP trial results: obeldesivir as post-exposure prophylaxis for Bundibugyo Ebola
AP (Oct 3, 2026) detailed the EBO-PEP trial: Gilead's obeldesivir pill given within 5 days of exposure to asymptomatic contacts of Bundibugyo cases (adults and children 12+), half placebo, 21 days daily monitoring + day-42 call. 250+ enrolled of ~1,000 target as of Oct 3; trial began July 2026 in Ituri. Coordinated by ALIMA with DRC's INRB and France's ANRS. Positive results would be the first efficacy evidence for any Bundibugyo-specific countermeasure (no approved vaccine or treatment exists); negative results would leave Ervebo cross-protection as the only prophylaxis option.
one-shot· Fires when ALIMA/Gilead or investigators report topline EBO-PEP results (infection rates in obeldesivir vs placebo arms among exposed contacts), or when enrollment completes / the trial is stopped.
Watch
US Title 42 Ebola travel restriction — expansion, lifting, or legal challenge
CDC's Title 42 order (interim final rule under 42 CFR 71.40, May 22, 2026) bars travelers — including U.S. citizens and lawful permanent residents — who have been in the DRC (originally also Uganda, South Sudan) within 21 days from boarding U.S.-bound flights. HHS disclosed Sept 28, 2026 that the U.S. has committed $1B+ to the response with 500+ CDC staff. Watch for expansion (additional countries, longer windows, new screening airports), lifting as transmission falls, or legal/congressional challenge.
ongoing· Fires on any formal change to the Title 42 Ebola entry restriction: expansion to more countries or longer exposure windows, formal lifting as the DRC outbreak recedes, or a court/congressional action against the order.
Watch
Revived political/OMB control of NIH grantmaking (EO revival, Uniform Guidance rule, or guidance workaround)
The Sept 2026 EO giving OMB veto power over NIH grants was dropped after bipartisan pushback (Collins, Murray, DeLauro), but the underlying May 2026 Uniform Guidance proposed rule — political-appointee review of discretionary grants, easier "for convenience" terminations — is only delayed by the CR funding the government through mid-December. Watch for: revival of the EO, movement on the Uniform Guidance rule at the December funding deadline, or equivalent political grant-review imposed via guidance.
ongoing· Fires on any formal action imposing political/OMB review of NIH or federal research grants: revived EO, Uniform Guidance rule implementation after the CR delay expires mid-December, or guidance-based workarounds.
Watch
Tampa Bay dengue outbreak escalation (emergency orders, spread, deaths)
Hillsborough, Pasco, and Pinellas counties declared local dengue emergencies Sept 23-24, 2026 (orders expire after 7 days unless extended). Hillsborough has 170 locally acquired cases (154 DENV-2) and Florida's first dengue death of 2026. Watch for: emergency-order extensions, declarations by additional counties or the state, sustained case growth (36 new cases in Hillsborough Sept 13-19), further deaths, or spread into new regions of Florida.
ongoing· Fires on material escalation: new county/state emergency declarations, further dengue deaths, or continued weekly case growth in Tampa Bay.
Watch
UNGA vote on PPPR Political Declaration (expected December 2026)
Follow-on to the Sept 25, 2026 HLM where US objection blocked consensus adoption. Health Policy Watch: the vote is "likely to occur just before the close of the Assembly's annual session in December." Watch whether the GA adopts the declaration by vote (with what language), further defers it, or the text collapses. PABS annex negotiations continue in parallel toward a May 2027 WHA target.
one-shotExpected Dec 31, 2026· Fires when the UNGA takes the PPPR Political Declaration to a vote (expected just before the December session close) or when adoption is further deferred.
Watch
FDA final PMA decision on GRAIL's Galleri MCED test
Follow-on to the Sept 23, 2026 advisory panel endorsement (10-0 safety, 6-4 effectiveness, 7-2 benefit-risk). FDA is not bound by panel advice. Outside analysts (RBC) expect a decision late 2026-early 2027; approval would make Galleri the first FDA-authorized MCED screening test and open Medicare/insurer reimbursement.
one-shot· Fires when FDA issues its formal PMA decision on Galleri: approval, denial, or any further review action. No fixed PDUFA date; decision expected around H1 2027.
Watch
Telix shareholder vote (EGM) on ITM acquisition
Telix's acquisition of ITM ($1.65B upfront + up to $700M in ITM-11 milestones) is subject to Telix shareholder approval at an EGM expected November 2026, plus regulatory approvals, with closing expected by end of FY2026. Fires on the EGM vote outcome or any deal termination/regulatory block. The deal's $100M first milestone hinges on FDA approval of ITM-11 in G1-G2 GEP-NETs by Dec 31, 2027 — tracked via the separate ITM-11 NDA resubmission watch.
one-shotExpected Nov 30, 2026· Fires when Telix shareholders vote on the ITM acquisition (EGM expected November 2026) or when the deal is terminated/blocked.
Question
Will CSTE's standardized measles-death definition and NCHS death-certificate reviews resolve the Pennsylvania death-count standoff?
CDC Director Schwartz said the agency asked the Council of State and Territorial Epidemiologists (CSTE) to develop a formal standardized definition of a measles-related death, and is waiting on NCHS reviews to confirm measles as underlying cause on PA death certificates. The outcome determines whether the CDC's national tally (currently zero deaths despite 3,471 cases) ever absorbs Pennsylvania's four measles-associated deaths — the core of the Kennedy–Shapiro standoff and an input to PAHO's November 2026 elimination-status review. Watch for CSTE definition adoption, NCHS review outcomes, or any CDC tally change.
Watch
FDA final decision on proposed withdrawal of Tavneos (avacopan) approval
FDA has proposed withdrawing Tavneos's U.S. approval (following NEJM's June 2026 retraction of ADVOCATE and the EC's August 2026 EU withdrawal), and FDA's March 2026 Drug Safety Communication counted 76 causally associated liver-injury cases including 8 deaths. Amgen stated Sept 19, 2026 (via Gastroenterology & Endoscopy News) that it plans to keep the drug on the market and contests withdrawal. Watch for the FDA's formal withdrawal decision, any Amgen hearing/appeal outcome, or a voluntary Amgen withdrawal.
one-shot· Fires on any formal FDA action concluding the withdrawal proposal: withdrawal effected, proposal dropped, or a hearing outcome.
Watch
LZ 700-day dark matter analysis — does the 2.6-sigma candidate event replicate?
LZ collaboration (LBNL/Bristol et al.) presented a 2.6-sigma candidate WIMP event (June 2023 recoil, 0.5% background probability) on Sept 1, 2026 at TeV Particle Astrophysics 2026, submitted to PRL. A 700-day dataset is now under blinded analysis with synthetic-event injection. Watch for the next LZ result release: additional high-energy recoils would push toward a 5-sigma dark matter claim; absence would kill the candidate. Independent cross-checks: XENONnT (Italy), PandaX-4T (China).
one-shot· Fires when the LZ collaboration publishes/presents its 700-day dataset analysis (submitted PRL paper pipeline; no fixed date).
Watch
Novo files for Wegovy label expansion to ages 6–<12 (STEP Young)
Following positive Phase 3 STEP Young results (40.4% of children 6–<12 left the obesity range at 68 weeks vs 0% placebo), watch for Novo to announce a regulatory submission (sNDA/label extension) to the FDA for Wegovy in ages 6–<12, and any FDA action. Off-label prescribing in 8–11-year-olds already rose from 0.03% (2019) to 9.3% (2026), so a filing would formalize a rapidly growing practice.
one-shot· Fires when Novo formally announces filing for a pediatric (6–<12) obesity indication for Wegovy, or when FDA acts on such a filing.
Watch
Skyhawk FALCON-HD Phase 2/3 readout for SKY-0515 in Huntington's disease
The Phase 2/3 FALCON-HD pivotal program (NCT06873334 004-ANZ, fully enrolled with 144 participants in Australia/NZ; NCT07378644 004-WW, ~600 participants recruiting across 40+ sites) will test whether SKY-0515's Phase 1/2 signals (+1.59 cUHDRS vs external control at Month 15, >60% mHTT knockdown) hold in placebo-controlled pivotal testing. Fires when Skyhawk reports topline FALCON-HD results.
one-shot· No announced readout date; 004-WW enrollment (~600 participants) is the pacing item. Watch for enrollment completion announcements and interim data disclosures.
Watch
Vera Therapeutics sBLA submission for Trutakna full approval in IgAN
Following the positive ORIGIN 3 final efficacy analysis (eGFR stabilized, 76% composite progression risk reduction, HR 0.24) announced Sept 15, 2026, Vera plans to submit a supplemental BLA in Q4 2026 seeking conversion of Trutakna's accelerated approval to full approval in IgAN, with a potential FDA decision in 2027. Fires when the sBLA submission is formally announced.
one-shotExpected Dec 31, 2026· Vera plans sBLA submission in Q4 2026 per CEO Marshall Fordyce's Sept 15, 2026 statement; full approval potentially 2027.
Watch
FDA selects first 8–10 Expedited IND Pilot sponsor-QRI pairs
Follow-on to the launched Expedited IND Pilot: applications close Oct 30, 2026; FDA expects to select 8–10 sponsor-QRI pairs for the initial cohort. Watch for the announcement of selected pairs and any early rolling-review outcomes.
one-shotExpected Dec 31, 2026· Fires when the FDA announces the selected sponsor-QRI pairs (or any interim program action) for the Expedited IND Pilot's initial cohort.
Watch
FDA PDUFA decision on ivonescimab BLA (EGFR-mutated NSCLC)
FDA decision on Summit/Akeso's BLA for ivonescimab in EGFR-mutated NSCLC post-TKI, based on the HARMONi trial (updated OS HR 0.76, nominal p=0.0151). PDUFA date Nov 14, 2026 per Summit's 8-K. Approval would make ivonescimab the first PD-1/VEGF bispecific approved in the U.S.
one-shotExpected Nov 14, 2026· Fires when the FDA grants approval, issues a CRL, or extends the review for the ivonescimab BLA on or around the Nov 14, 2026 PDUFA date.
Watch
Initiation of experimental H5N1 vaccine trials in Australian sea lions
Monitor whether South Australia or the Australian federal government initiates experimental H5N1 vaccination trials for endangered Australian sea lions at Seal Bay or other colonies.
one-shot· South Australian Government / Australian Federal Government
Watch
Full Phase 3 Lp(a)HORIZON trial data presentation
Monitor the presentation of the full Phase 3 Lp(a)HORIZON clinical trial results for pelacarsen at an upcoming medical congress to assess subpopulation and biomarker analyses.
one-shot· Novartis / Ionis
Watch
NMPA regulatory decision on Tam-Peli (tambotatug pelitecan) in SCLC
Monitor the Chinese National Medical Products Administration (NMPA) regulatory decision on the priority review New Drug Application (NDA) for Tam-Peli (tambotatug pelitecan; YL201) in recurrent small-cell lung cancer (SCLC).
one-shotExpected Jun 30, 2027· Fires when the Chinese NMPA grants approval or issues a rejection for Tam-Peli in recurrent SCLC.
Watch
FDA priority review decision on Novartis's delpacibart zotadirsen (del-zota) in DMD44
Monitor the FDA's regulatory decision (accelerated approval or Complete Response Letter) on Novartis's Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for patients with Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44), following its priority review acceptance.
one-shotExpected Feb 28, 2027· Fires when the FDA issues its regulatory decision on the del-zota BLA in DMD44.
Watch
FDA regulatory filing and decision on Imdelltra + Imfinzi in first-line ES-SCLC
Monitor the regulatory filings and subsequent FDA approval decision for Amgen and AstraZeneca's Imdelltra (tarlatamab-dlle) in combination with Imfinzi (durvalumab) for first-line maintenance in extensive-stage small cell lung cancer (ES-SCLC) following the positive Phase 3 DeLLphi-305 trial.
one-shotExpected Jun 30, 2027· Fires when the FDA grants approval or issues a CRL for the Imdelltra + Imfinzi combination as a first-line maintenance treatment in ES-SCLC.
Watch
FDA regulatory decision on Nanoscope's MOGENRY (MCO-010) BLA in retinitis pigmentosa
Monitor the FDA's final regulatory decision (approval or complete response letter) on Nanoscope Therapeutics' BLA for MOGENRY (sonpiretigene isteparvovec, MCO-010) for the treatment of retinitis pigmentosa.
one-shotExpected Jul 31, 2027· Fires when the FDA grants approval or issues a CRL for MCO-010 in retinitis pigmentosa.
Watch
EMA regulatory decision on Takeda's rusfertide (Mimrylo) in polycythemia vera
Monitor the EMA's Committee for Medicinal Products for Human Use (CHMP) opinion and subsequent European Commission decision on rusfertide (Mimrylo) for the treatment of polycythemia vera.
one-shotExpected Jun 30, 2027· Fires when the EMA issues its regulatory decision on the marketing authorization application for rusfertide in Europe.
Watch
EMA regulatory decision on Ionis' zilganersen (Zanvastro) in Alexander disease
Monitor the EMA's Committee for Medicinal Products for Human Use (CHMP) opinion and subsequent European Commission decision on zilganersen (Zanvastro) for the treatment of Alexander disease.
one-shotExpected Jun 30, 2027· Fires when the EMA issues its regulatory decision on the marketing authorization application for zilganersen in Europe.
Watch
FDA traditional approval and confirmatory trial results for camizestrant in breast cancer
Monitor the FDA's traditional approval decision or subsequent clinical trial readouts (e.g. overall survival or other Phase III trials like SERENA-4) for camizestrant (Etcamah) in HR-positive, HER2-negative advanced breast cancer following its accelerated approval.
one-shotExpected Dec 31, 2027· Fires when the FDA grants traditional approval or when AstraZeneca reports confirmatory overall survival data for camizestrant.
Watch
FDA regulatory decision on uniQure's AMT-130 BLA in Huntington's disease
Monitor the FDA's final regulatory decision (approval or complete response letter) on uniQure's Biologics License Application (BLA) for AMT-130 in Huntington's disease.
one-shot· Fires when the FDA grants accelerated approval or issues a Complete Response Letter (CRL) for AMT-130 in Huntington's disease.
Watch
Cytokinetics sNDA submission for aficamten in symptomatic nHCM
Monitor Cytokinetics' planned submission of a supplemental New Drug Application (sNDA) to the FDA for aficamten (MYQORZO) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), targeted for Q4 2026.
one-shotExpected Dec 31, 2026· Fires when Cytokinetics formally submits the sNDA for aficamten in symptomatic nHCM.
Watch
FDA regulatory decision on Capricor's deramiocel BLA in DMD
Monitor the FDA's final regulatory decision on Capricor's Biologics License Application (BLA) for deramiocel in Duchenne muscular dystrophy (DMD) on or before its new extended PDUFA date of November 22, 2026.
one-shotExpected Nov 22, 2026· Fires when the FDA grants approval or issues a Complete Response Letter (CRL) for deramiocel on or before November 22, 2026.
Watch
RecovryAI De Novo submission for generative AI Virtual Care Assistant
Monitor RecovryAI's formal De Novo classification request submission to the FDA for its generative AI-based Virtual Care Assistant post-surgery recovery tool, planned for Q4 2026.
one-shotExpected Dec 31, 2026· Fires when RecovryAI formally submits its De Novo request to the FDA.
Watch
EMA regulatory decision on Regeneron's garetosmab (Pasatru) in FOP
Monitor the EMA's Committee for Medicinal Products for Human Use (CHMP) opinion and subsequent European Commission decision on garetosmab (Pasatru) for the treatment of FOP following the regulatory submission in Q1 2026.
one-shot· Regeneron / EMA
Watch
Xspray Pharma NDA resubmission for Dasynoc
Monitor Xspray's formal resubmission of its NDA for Dasynoc to the FDA following the resolution of NerPharMa's manufacturing deficiencies and the generation of consecutive commercial-scale batch data.
one-shot· Xspray Pharma
Watch
argenx BLA submission for Vyvgart Hytrulo in autoimmune myositis
Monitor argenx's Biologics License Application (BLA) submission to the FDA for Vyvgart Hytrulo in autoimmune myositis following positive Phase III ALKIVIA results.
one-shotExpected Mar 31, 2027· Fires when argenx formally submits its BLA to the FDA for Vyvgart Hytrulo in adults with autoimmune myositis.
Watch
BMS full Phase 3 EXCALIBER-RRMM data presentation
Monitor the presentation of the full Phase III EXCALIBER-RRMM clinical trial results for Zenbexus (iberdomide), including progression-free survival (PFS) data.
one-shotExpected Dec 31, 2026· Fires when Bristol Myers Squibb presents full results, including PFS and overall survival, from the Phase III EXCALIBER-RRMM trial.
Watch
Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP
Monitor the initiation and enrollment of Regeneron's Phase III OPTIMA 2 clinical trial of Pasatru (garetosmab-grts) in pediatric and adolescent patients with fibrodysplasia ossificans progressiva (FOP).
one-shotExpected Dec 31, 2026· Fires when Regeneron formally initiates clinical trial sites or starts enrolling pediatric patients for the Phase III OPTIMA 2 trial.
Watch
Launch of JAXA's Martian Moons eXploration (MMX) mission
Monitor the launch of JAXA's MMX spacecraft aboard H3 Launch Vehicle flight No. 10 from Tanegashima Space Center to collect samples from Phobos.
one-shotExpected Oct 20, 2026· JAXA
Watch
Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma
Monitor the formal regulatory submission (BLA) of the Merck/Moderna mRNA cancer vaccine (intismeran autogene / V940) in combination with Keytruda for completely resected Stage IIB-IV melanoma to the FDA.
one-shotExpected Dec 31, 2026· Fires when Merck and Moderna formally submit their BLA to the FDA for intismeran autogene in resected melanoma.
Watch
PAHO decision on U.S. measles elimination status
Monitor the official announcement by the Pan American Health Organization (PAHO) in November 2026 on whether the United States will lose its measles elimination status due to ongoing domestic transmission chains.
one-shotExpected Nov 30, 2026· PAHO / CDC
Watch
Summit/Akeso Phase III HARMONi-3 trial results of ivonescimab in first-line NSCLC
Monitor the topline Phase III HARMONi-3 trial results for ivonescimab in first-line NSCLC, expected in H2 2026, to assess if global PFS benefits are replicated or show similar degradation as seen in China's HARMONi-6.
one-shotExpected Dec 31, 2026· Fires when Summit reports topline Phase III HARMONi-3 results.
Watch
FDA regulatory decision on BMS's mezigdomide NDA in multiple myeloma
Monitor the FDA's regulatory decision on BMS's second CELMoD therapy, mezigdomide, in combination with carfilzomib and dexamethasone, on or before its PDUFA date of May 13, 2027.
one-shotExpected May 13, 2027· Bristol Myers Squibb / FDA
Watch
ITM NDA resubmission for ITM-11 in GEP-NETs
Monitor ITM's resubmission of its NDA for ITM-11 to the FDA following the resolution of the CMC and third-party commercial facility deficiencies cited in the August 2026 CRL.
one-shot· ITM Isotope Technologies Munich
Watch
FDA regulatory decision on Belite Bio's tinlarebant NDA in Stargardt disease
Monitor the FDA's regulatory decision (approval or complete response letter) on Belite Bio's NDA for tinlarebant in Stargardt disease type 1, with a PDUFA target action date of February 12, 2027.
one-shotExpected Feb 12, 2027· Fires when the FDA issues its regulatory decision on the tinlarebant NDA for STGD1 on or before the PDUFA target action date of February 12, 2027.
Watch
Tarsus/Alkeus Phase 3 NORTHSTAR trial results of gildeuretinol in Stargardt disease
Monitor the Phase 3 NORTHSTAR trial results for Tarsus/Alkeus's oral gildeuretinol in Stargardt disease, expected in the second half of 2029.
one-shotExpected Dec 31, 2029· Fires when Tarsus reports topline Phase 3 NORTHSTAR data for gildeuretinol in Stargardt disease.
Watch
Replimune Phase 3 IGNYTE-3 confirmatory trial results for Tudriqev in melanoma
Monitor the Phase 3 IGNYTE-3 randomized confirmatory trial results for Replimune's Tudriqev in advanced melanoma (expected by late 2027), which is required to support its accelerated approval.
one-shotExpected Dec 31, 2027· Fires when Replimune reports topline Phase 3 IGNYTE-3 confirmatory trial data for Tudriqev + nivolumab in advanced melanoma.
Watch
FDA final regulatory decision on Saol's SL1009 (DCA) in PDCD
Monitor the FDA's final regulatory decision (approval or complete response letter) on Saol Therapeutics' resubmitted NDA for SL1009 (sodium dichloroacetate) in pyruvate dehydrogenase complex deficiency (PDCD) on or before the PDUFA target action date of December 30, 2026.
one-shotExpected Dec 30, 2026· Fires when the FDA grants approval or issues a CRL for SL1009 (DCA) in PDCD on its PDUFA date of December 30, 2026.
Watch
FDA final decision on compounding peptides 503A list addition
Monitor the FDA's formal administrative decision and rulemaking on whether to adopt the Pharmacy Compounding Advisory Committee's (PCAC) July 2026 recommendations to add BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the 503A bulk drug substances list.
one-shotExpected Jun 30, 2027· Fires when the FDA publishes a final rule, guidance, or administrative decision regarding the addition of the six recommended peptides to the 503A bulk compounding list.
Watch
FDA response to CRL public disclosure citizen petition (Docket FDA-2026-P-4369)
Monitor the FDA's formal administrative response to the citizen petition (Docket No. FDA-2026-P-4369-0001) filed by an unnamed pharmaceutical company seeking to halt the proactive publication of Complete Response Letters.
one-shotExpected Oct 17, 2026· Fires when the FDA issues its formal response to the citizen petition seeking to halt the proactive publication of Complete Response Letters.
Watch
New Zealand H5N1 transmission to poultry or wildlife sanctuaries
Monitor whether the newly arrived H5N1 bird flu strain spreads to New Zealand's commercial poultry flocks, native wildlife sanctuaries (like Pūkaha Mount Bruce), or causes mass mortality in native wild bird colonies or marine mammals.
ongoing· Fires when New Zealand confirms H5N1 transmission to commercial poultry operations, wildlife sanctuaries, or local marine mammal colonies.
Watch
FDA final rule on Complete Response Letter public disclosure (RIN 0910-AJ16)
Monitor the FDA's proposed rule (RIN 0910-AJ16) to formalize the Complete Response Letter (CRL) transparency policy and eliminate the presumption of commercial confidentiality for unapproved marketing applications.
one-shotExpected Mar 31, 2027· Fires when the FDA publishes its final rule (RIN 0910-AJ16) or takes further formal administrative action to permanently codify the CRL public disclosure policy.
Watch
Australia H5N1 transmission to poultry or local wildlife
Monitor whether the newly arrived H5N1 avian influenza strain jumps from migratory seabirds to local Australian wildlife, marine mammals (e.g. fur seals), or commercial poultry farms.
ongoing· Fires when Australia confirms the transmission of H5N1 to commercial poultry flocks, native land birds, or local marine mammal colonies.
Watch
Sobi BLA resubmission for NASP in uncontrolled gout
Monitor Sobi's resubmission of the BLA for NASP (nanoencapsulated sirolimus plus pegadricase) in uncontrolled gout following the resolution of CMC and contract manufacturing facility deficiencies.
one-shot· Fires when Sobi formally resubmits its BLA for NASP to the FDA after addressing the manufacturing deficiencies cited in the June 2026 CRL.
Watch
Achieve Life Sciences NDA resubmission for cytisinicline in smoking cessation
Monitor Achieve Life Sciences' planned NDA resubmission in Q4 2026 for cytisinicline in smoking cessation, naming Adare Pharma Solutions as its primary manufacturer.
one-shotExpected Dec 31, 2026· Fires when Achieve Life Sciences formally submits its resubmitted NDA for cytisinicline to the FDA.
Watch
EMA re-examination outcome on Omeros's narsoplimab in TA-TMA
Monitor Omeros's request for re-examination of the negative CHMP opinion for narsoplimab in TA-TMA, the convening of the Ad Hoc Expert Group (AHEG), and the final decision.
one-shot· Fires when the EMA or Omeros announces the outcome of the re-examination and AHEG review.
Watch
GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP
Monitor the initiation of GondolaBio's global Phase 2b/3 PATHWAY trial of PORT-77 in patients with EPP and XLP, targeted for Q3 2026.
one-shotExpected Sep 30, 2026· Fires when GondolaBio begins enrolling patients or initiates clinical sites for the Phase 2b/3 PATHWAY trial of PORT-77 in EPP/XLP.
Watch
Merck regulatory filing for tulisokibart in ulcerative colitis
Monitor Merck's formal regulatory filing (BLA/NDA) to the FDA for tulisokibart (MK-7240) in moderately to severely active ulcerative colitis (UC) following the successful Phase 3 ATLAS-UC program.
one-shotExpected Mar 31, 2027· Fires when Merck submits its regulatory application for tulisokibart in ulcerative colitis.
Watch
MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa
Monitor MoonLake's planned Biologics License Application (BLA) submission to the FDA for sonelokimab (SLK) in moderate-to-severe hidradenitis suppurativa (HS), targeted for late September 2026, and subsequent FDA PDUFA date allocation in late November 2026.
one-shotExpected Sep 30, 2026· Fires when MoonLake formally submits the BLA for sonelokimab in HS.
Watch
FDA regulatory decision on Exelixis' zanzalintinib plus Tecentriq in late-line mCRC
Monitor the FDA's regulatory decision on Exelixis' New Drug Application (NDA) for zanzalintinib plus Tecentriq in late-line metastatic colorectal cancer (mCRC), with a PDUFA target action date of December 3, 2026.
one-shotExpected Dec 3, 2026· Fires when the FDA grants or denies approval for zanzalintinib plus Tecentriq in late-line mCRC.
Watch
FDA traditional approval decision on Novartis's Vanrafia (atrasentan) in IgAN
Monitor the FDA's regulatory decision on converting Novartis's Vanrafia (atrasentan) accelerated approval to traditional approval, supported by the final 2.5-year ALIGN trial results published in June 2026. Submissions are planned for late 2026.
one-shotExpected Dec 31, 2026· Novartis
Watch
Dianthus MoMeNtum Phase 2 top-line data in MMN
Monitor Dianthus's release of top-line Phase 2 MoMeNtum data for claseprubart in Multifocal Motor Neuropathy (expected in Q4 2026).
one-shotExpected Dec 31, 2026· Dianthus Therapeutics
Watch
Dianthus CAPTIVATE Part B top-line guidance in CIDP
Monitor Dianthus's release of top-line guidance for Part B of the Phase 3 CAPTIVATE trial in CIDP (expected by year-end 2026).
one-shotExpected Dec 31, 2026· Dianthus Therapeutics
Watch
FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP
Monitor the FDA regulatory decision on Gilead's supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV PrEP.
one-shotExpected Feb 2, 2027· Fires when the FDA grants or denies approval for once-weekly oral Yeztugo for HIV PrEP (PDUFA date: February 2, 2027).
Watch
FDA regulatory decision on Zepzelca's second-line SCLC indication
Monitor the FDA's regulatory decision or next steps regarding Jazz/PharmaMar's Zepzelca (lurbinectedin) accelerated approval for second-line SCLC following the Phase 3 LAGOON trial failure.
one-shot· Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca.
Watch
USDA $750M sterile screwworm fly facility operational launch in Texas
Monitor the construction and operational launch of the USDA's $750 million sterile fly production facility in Texas designed to produce 300 million sterile New World screwworm flies per week.
one-shotExpected Dec 31, 2027· Fires when the USDA's new sterile fly facility in Texas begins operations.
Monitor the Phase 3 BETA-PRESERVE (NCT07088068) confirmatory study for Sanofi's Tzield (teplizumab-mzwv) in newly diagnosed Stage 3 Type 1 diabetes to verify clinical benefit following its accelerated approval.
one-shotExpected Dec 31, 2028· Fires when Sanofi reports topline safety and efficacy results from the Phase 3 BETA-PRESERVE trial.
Watch
FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination
Monitor the FDA regulatory submission and subsequent approval decision for Gilead and Merck's once-weekly oral HIV single-tablet regimen (islatravir/lenacapavir) following the positive Phase 3 ISLEND-1 and ISLEND-2 trials.
one-shotExpected Jun 30, 2027
Watch
FDA regulatory filing and decision on Takeda's zasocitinib in plaque psoriasis
Monitor the FDA regulatory submission and subsequent approval decision for Takeda's oral TYK2 inhibitor zasocitinib in moderate-to-severe plaque psoriasis, following the positive Phase 3 LATITUDE Atlas results.
one-shotExpected Apr 30, 2027
Watch
FDA regulatory filing and decision on Eli Lilly's Foundayo in Type 2 diabetes
Monitor the FDA regulatory submission and subsequent approval decision for Eli Lilly's oral GLP-1 Foundayo (orforglipron) in Type 2 diabetes, following the positive Phase 3 ACHIEVE program results.
one-shotExpected Apr 30, 2027
Watch
Sanofi riliprubart Phase 3 VITALIZE trial status and readout in CIDP
Monitor the regulatory/clinical status and readout of Sanofi's Phase 3 VITALIZE study of riliprubart in IVIg-experienced CIDP patients, following the early termination of the refractory MOBILIZE study.
one-shotExpected Jun 30, 2027· Fires when Sanofi reports results or makes a strategic decision to continue/terminate the Phase 3 VITALIZE study.
Watch
Dianthus Therapeutics claseprubart Phase 3 CAPTIVATE trial readout in CIDP
Monitor the Phase 3 CAPTIVATE clinical trial readout for Dianthus Therapeutics' claseprubart (DNTH-103) in IVIg-experienced CIDP patients to assess if classical complement pathway inhibition is effective in this distinct cohort.
one-shotExpected Jun 30, 2027· Fires when Dianthus Therapeutics reports topline Phase 3 CAPTIVATE safety and efficacy results.
Watch
Eli Lilly SURPASS T1D-1 Phase 3 trial readout in Type 1 Diabetes
Monitor the Phase 3 SURPASS T1D-1 clinical trial readout evaluating tirzepatide as an adjunct therapy in overweight/obese patients with Type 1 diabetes. This trial is highly anticipated following Roche's decision to halt acmopatide's T1D program.
one-shotExpected Nov 30, 2026· Fires when Eli Lilly reports topline Phase 3 SURPASS T1D-1 safety and efficacy results.
Watch
DIOSynVax AI-designed universal Sarbeco vaccine Phase II trial readout
Monitor the Phase II clinical trial readout for DIOSynVax's universal Sarbeco vaccine designed entirely by AI (enrolling over 200 participants).
one-shotExpected Jun 30, 2027· Fires when DIOSynVax or the University of Cambridge reports Phase II efficacy and safety data for the AI-designed universal Sarbeco vaccine.
Monitor the initiation of pivotal Phase 3 trial activities for ATH434 in Multiple System Atrophy (MSA) following FDA agreement.
one-shotExpected Dec 31, 2026· Fires when Alterity Therapeutics begins enrolling patients or initiates clinical sites for the Phase 3 ATH434 trial in MSA.
Watch
Disc Medicine bitopertin Phase 3 APOLLO trial readout and FDA CRL decision
Monitor the topline Phase 3 APOLLO trial results for bitopertin in EPP (expected Q4 2026) and the subsequent FDA regulatory decision on the CRL response (expected mid-2027).
one-shotExpected Jun 30, 2027· Fires when Disc Medicine reports Phase 3 APOLLO results or when the FDA grants/denies approval for bitopertin in EPP following the CRL response.
Watch
Pfizer berobenatide Phase 3 obesity trial readout
Monitor the first Phase 3 clinical trial results for Pfizer's monthly GLP-1 RA peptide berobenatide (PF-07933944) in obesity.
one-shotExpected Dec 31, 2027· Fires when Pfizer reports its first Phase 3 trial data for berobenatide in obesity (expected in 2H 2027).
Watch
Phase 3 trial readout for VGA039 in von Willebrand disease
Monitor the Phase 3 clinical trial readout for VGA039 in von Willebrand disease (VWD) to evaluate if the subcutaneous monoclonal antibody meets its primary safety and efficacy endpoints.
one-shotExpected Dec 31, 2028· Fires when the Phase 3 trial results for VGA039 in von Willebrand disease are published or presented.
Watch
ISS Russian Zvezda module air leaks and repairs
Monitor collaborative repairs and leak rates of the International Space Station's Russian Zvezda service module transfer tunnel (PrK) to assess long-term structural integrity and crew safety.
ongoing· Fires when new leaks are detected, emergency safe haven drills occur, or permanent repair solutions are implemented on the ISS Zvezda module.
Watch
FDA regulatory decision on giredestrant in HR+ early-stage breast cancer
Monitor the FDA regulatory decision on Roche's Biologics License Application (BLA) for the oral SERD giredestrant in HR+ early-stage adjuvant breast cancer following its priority review acceptance.
one-shotExpected Nov 30, 2026· Fires when the FDA grants or denies approval for giredestrant in HR+ early-stage breast cancer.
Watch
FDA regulatory decision on bezuclastinib in GIST
Monitor the FDA regulatory decision on Cogent Biosciences' New Drug Application (NDA) for the selective KIT inhibitor bezuclastinib in combination with sunitinib for Gleevec-resistant gastrointestinal stromal tumors (GIST).
one-shotExpected Nov 30, 2026· Fires when the FDA grants or denies approval for bezuclastinib in second-line Gleevec-resistant GIST.
Watch
Moderna Phase 3 mRNA-1018 bird flu vaccine trial readout
Monitor topline safety and immunogenicity readouts from Moderna's Phase 3 trial of mRNA-1018 (enrolling ~4,000 healthy adults in the US and UK).
one-shot· Moderna
Watch
sBLA submission for Zynlonta plus rituximab in r/r DLBCL
Monitor ADC Therapeutics' planned sBLA submission in Q4 2026 following the pre-sBLA meeting with the FDA in August 2026 to see if safety concerns (13.2% fatal TEAEs in LOTIS-5) delay or alter the regulatory path.
one-shotExpected Dec 31, 2026· ADC Therapeutics / FDA
Watch
NHS-Galleri trial cancer mortality data release
Monitor the release of final cancer-specific mortality data from the NHS-Galleri trial to evaluate if the Galleri multi-cancer early detection test successfully translates early detection into lives saved.
ongoing· Fires when peer-reviewed mortality outcomes or long-term follow-up analyses from the NHS-Galleri trial are published or presented.
Watch
NMPA regulatory decision on IBI343 (world's first CLDN18.2 ADC)
Monitor the Chinese National Medical Products Administration (NMPA) regulatory decision on the priority review New Drug Application (NDA) for IBI343 in CLDN18.2-positive gastric cancer.
one-shotExpected Feb 1, 2027· Fires when the Chinese NMPA grants or denies approval for IBI343 (arcotatug tavatecan) in advanced refractory CLDN18.2-positive gastric cancer.
Watch
Global Phase 3 trial readouts for ivonescimab (HARMONi studies)
Monitor readouts from global Phase 3 trials of ivonescimab (HARMONi-3 or HARMONi-7) to determine if the 34% overall survival benefit in squamous NSCLC is replicated in a diverse, global patient population.
ongoing· Fires when global Phase 3 data (HARMONi-3 or HARMONi-7) for ivonescimab is presented or published, evaluating global applicability and efficacy in older populations (>=65).
Track consequential science and health — disease outbreaks and public-health moves, drug approvals and major trial readouts, breakthroughs in biology/energy/space, and the policy around them. Lead with what's new, grounded in primary findings.